Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic Protocol for a Test-Negative Case-Control Study
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiad483 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Caren van Roekel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Infectious Disease Control, National Institute for Public Health and Environment, Bilthoven, the Netherlands. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human, Respiratory Tract Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: European Union, European Federation of Pharmaceutical Industries and Associations.
Abstract (Originalsprache)
Monitoring the real-life effectiveness of respiratory syncytial virus (RSV) products is of major public health importance. This generic protocol for a test-negative design study aims to address currently envisioned approaches for RSV prevention (monoclonal antibodies and vaccines) to study effectiveness of these products among target groups: children, older adults, and pregnant women. The generic protocol approach was chosen to allow for flexibility in adapting the protocol to a specific setting. This protocol includes severe acute respiratory infection (SARI) and acute respiratory infection (ARI), both due to RSV, as end points. These end points can be applied to studies in hospitals, primarily targeting patients with more severe disease, but also to studies in general practitioner clinics targeting ARI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Infectious Disease Control, National Institute for Public Health and Environment, Bilthoven, the Netherlands.
- Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland.
- Department of Pediatrics, University of Turku and Turku University Hospital, Turku, Finland.
- Sanofi Pasteur, SA, Lyon, France.
- Pfizer, Ltd, NewYork City, New York, USA.
ORCID-Profile: Caren van Roekel, Eero Poukka, Topi Turunen, Lance Presser, Adam Meijer, Terho Heikkinen, Rolf Kramer, Elizabeth Begier
Förderung
- European Union
- European Federation of Pharmaceutical Industries and Associations
Zitieren
APA
van Roekel, C., Poukka, E., Turunen, T., Nohynek, H., Presser, L., Meijer, A., Heikkinen, T., Kramer, R., Begier, E., Teirlinck, A. C., Knol, M. J., & PROMISE Investigators (2024). Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic Protocol for a Test-Negative Case-Control Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad483
Vancouver
van Roekel C, Poukka E, Turunen T, Nohynek H, Presser L, Meijer A, et al. Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic Protocol for a Test-Negative Case-Control Study. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad483
BibTeX
@article{vanRoekel2024,
author = {van Roekel, Caren and Poukka, Eero and Turunen, Topi and Nohynek, Hanna and Presser, Lance and Meijer, Adam and Heikkinen, Terho and Kramer, Rolf and Begier, Elizabeth and Teirlinck, Anne C and Knol, Mirjam J and PROMISE Investigators, PROMISE Investigators},
title = {Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic Protocol for a Test-Negative Case-Control Study},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiad483}
}
EUVIMED